DPMS produces approximately 40% of Dechra’s pharmaceuticals and manufactures for a limited number of third parties on a contract basis. It’s objectives are to produce Dechra’s product range efficiently to the highest quality standards, to maintain a reliable supply chain and to contribute profit to the business through third party manufacturing.
A total of 710 employees worked in the DPMS division as of the FY22 year end.
Our manufacturing sites at Skipton, Bladel and Zagreb also include Pharmaceutical Development, Quality Control (QC) and Stability Testing and Validation Laboratories.
The site at Skipton offers a comprehensive range of manufacturing and packing services, principally for CAP. It is a centre of excellence in solid forms for tablets and capsules, liquids, creams, ointment products and terminal sterilisation.
Bladel, the Netherlands
The site at Bladel manufactures water soluble powder and premix products for food producing animals in large-scale batches. It is also a centre for aseptic filling and for sterile injectables for both FAP and CAP.
It produces and develops egg based vaccines. It also produces liquids in various scales and formats and is currently being expanded to be a second source of solid dose tablets.
Fort Worth, Texas USA
This site manufactures solid dose, liquids, creams and ointments for the North American market.
Melbourne, Florida USA
It is a centre of excellence in manufacturing palatable and chewable tablets.
This site produces a wide range of vaccines for multi species predominately for South America and selected export markets.
This site produces a broad portfolio of dosage types for the Australian and New Zealand markets including tablets and liquids.
Pomona, California USA
In August 2022, we completed our most recent company acquisition when acquiring Med-Pharmex, Inc, a leading veterinary pharmaceutical manufacturer. It has expertise in topical, oral and certain injectible products.
This transaction provides further scale to our operations in the USA and the manufacturing facilities provide additional capacity for the Group to utilise for its own manufacturing strategy over time.